Clinical Trial Update: Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Iressa (gefitinib) vs placebo as maintenance therapy in locally advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Carcinoma | Phase 3 | Status: TERMINATED